Back to blog

Donald C Moore

Donald C Moore, PharmD, BCPS, BCOP, DPLA
Pharmacist Clinical Coordinator – Hematology/Oncology Levine Cancer Institute Concord, NC

Urothelial Carcinoma, Medical Oncology, Fibroblast Growth Factor Receptor (FGFR) Inhibitor, Urothelial cancer, New Drugs, Issue1

Erdafitinib for the Treatment of Urothelial Carcinoma

Donald C Moore Donald C Moore

Erdafitinib (Balversa®, Janssen Products, LP) is a novel fibroblast growth factor receptor (FGFR) inhibitor recently approved by the FDA for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with a susceptible FGFR3 or FGFR2 genetic alteration who have ...

Read more